Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Genotype IV Infected Egyptian Patients

NCT01758939 is registered in ClinicalTrials.gov with Cairo University as lead sponsor.

NCT NCT01758939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01758939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Genotype IV Infected Egyptian Patients
Lead sponsor
Cairo University
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2011
Completion date
January 31, 2017
Enrollment
100,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic